Get the Stockscreener App
25.56
3.07%
-0.81
Janux Therapeutics Inc stock is traded at $25.56, with a volume of 742.30K.
It is down -3.07% in the last 24 hours and down -4.73% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$26.37
Open:
$26.25
24h Volume:
742.30K
Relative Volume:
0.81
Market Cap:
$1.94B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-22.03
EPS:
-1.16
Net Cash Flow:
$-37.82M
1W Performance:
-22.26%
1M Performance:
-4.73%
6M Performance:
-52.60%
1Y Performance:
-50.79%
1-Day Range:
$25.44
$28.13
1-Week Range:
$24.13
$31.39
52-Week Range:
$22.52
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
25.56 | 1.94B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc - TipRanks
Janux Therapeutics price target lowered to $36 from $41 at Scotiabank - TipRanks
Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus
Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus
Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position - TipRanks
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback - TipRanks
Janux Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus
Janux Therapeutics reports Q1 EPS (38c), consensus (39c) - TipRanks
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling - Defense World
Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks
Janux commences Phase Ib studies in trial for prostate cancer treatment - Yahoo
Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007 - TipRanks
Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007 - TipRanks
Janux Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Insider Monkey
Janux Therapeutics begins phase 1b trial for prostate cancer therapy - Investing.com
Janux Therapeutics begins phase 1b trial for prostate cancer therapy By Investing.com - Investing.com India
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Insider Monkey
Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential - Insider Monkey
Janux Therapeutics (JANX) to Release Earnings on Tuesday - Defense World
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
A new trading data show Janux Therapeutics Inc (JANX) is showing positive returns. - Sete News
Learn to Evaluate (JANX) using the Charts - news.stocktradersdaily.com
Trading Day Review: Janux Therapeutics Inc (JANX) Loses Momentum, Closing at 32.05 - DWinneX
Should Janux Therapeutics Inc (NASDAQ: JANX) Rally After -123.74% Drop From High? - Marketing Sentinel
Wells Fargo & Company MN Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Are Janux Therapeutics Inc’shares a good deal? - uspostnews.com
Latest Insider moments: Meyer Andrew Hollman, Janux Therapeutics Inc [JANX] Chief Business Officer sold 3,334 shares – Knox Daily - knoxdaily.com
Russell Investments Group Ltd. Buys 442 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics Inc (JANX) Worth Considering For The Next Few Weeks - Stocksregister
Legal & General Group Plc Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - American Banking and Market News
LPL Financial LLC Makes New $439,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Financial Metrics Exploration: Understanding Heron Therapeutics Inc (HRTX) Through Ratios - DWinneX
Cerity Partners LLC Acquires Shares of 4,478 Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Janux Therapeutics Inc (JANX)’s stock chart: A technical perspective - uspostnews.com
Janux Therapeutics Inc [JANX] Shares Rise 5.36 % on Wednesday - knoxdaily.com
Oncology’s Most Eligible Unpartnered Assets - insights.citeline.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Invesco Ltd. - Defense World
Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
JPMorgan Chase & Co. Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Sei Investments Co. - Defense World
Janux Therapeutics Inc (JANX)’s stock price in review: A technical analysis - uspostnews.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Vanguard Group Inc. - Defense World
Janux Therapeutics stock hits 52-week low at $23.72 By Investing.com - Investing.com South Africa
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):